Metabolism Drugs Market - Size, Share, Trends, and Forecast, 2022 - 2028

Metabolism Drugs Market - Size, Share, Trends, and Forecast, 2022 - 2028

Increasing prevalence of pompe disease is expected to create lucrative opportunities for pharmaceutical manufacturers to develop and commercialize novel treatments for the disease. For instance, according to United Pompe Foundation (UPF), 2021, the estimated incidence of Pompe disease in Holland is 1 in 40,000, in Southern China and Taiwan: 1 in 50,000 births, African-Americans: 1 in 14,000 births and in Caucasian is 1 in 100,000 population. Initiatives from government organizations for drug research and development is supporting growth of the metabolism drugs market.
For instance, in 2016, the scientist from National Institutes of Health researchers collaborated with National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS) and researchers identified a new molecule that shows promising approach for treatment of the rare gaucher disease. Moreover, in 2014, European Gaucher Alliance launched Gaucher Awareness Day to spread awareness about this rare disease among the population in Europe.
Market Dynamics
Robust pipeline with various therapies such as enzyme replacement therapy, gene therapy, and small molecule drugs is expected to boost the metabolism drugs market over the forecast period. Increased understanding of diseases and rising number of diagnosed patients are expected to increase the number of patients undergoing treatment.
High prevalence of metabolic diseases is expected to support the growth of the metabolism drugs market. For instance, according to the National Institute of Health (NIH) 2018 report, frequency of hunter syndrome is 1 in 100,000 to 1 in 160,000 in males. Enzyme replacement therapy is expected to show significant growth in the metabolism drugs market over the forecast period.
Key features of the study:

This report provides in-depth analysis of metabolism drugs market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new application launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global metabolism drugs market based on the following parameters – company overview, financial performance, application portfolio, geographical presence, distribution strategies, key developments, and strategies
Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future application launches, technology up-gradation, market expansion, and marketing tactics
The global metabolism drugs market report caters to various stakeholders in this industry including investors, suppliers, application manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the metabolism drugs market

Detailed Segmentation:

Global Metabolism Drugs Market, By Therapy Type:

Enzyme Replacement Therapy
Substrate Reduction Therapy
Small Molecule Drugs
Others

Global Metabolism Drugs Market, By Application:

Glycogen Metabolism Disease
Lipid Metabolism Disease
Amino Acid Metabolism Disease
Others

Global Metabolism Drugs Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Metabolism Drugs Market, By Geography:

North America

By Therapy Type:

Enzyme Replacement Therapy
Substrate Reduction Therapy
Small Molecule Drugs
Others

By Application:

Glycogen Metabolism Disease
Lipid Metabolism Disease
Amino Acid Metabolism Disease
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

U.S.
Canada

Europe

By Therapy Type:

Enzyme Replacement Therapy
Substrate Reduction Therapy
Small Molecule Drugs
Others

By Application:

Glycogen Metabolism Disease
Lipid Metabolism Disease
Amino Acid Metabolism Disease
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Therapy Type:

Enzyme Replacement Therapy
Substrate Reduction Therapy
Small Molecule Drugs
Others

By Application:

Glycogen Metabolism Disease
Lipid Metabolism Disease
Amino Acid Metabolism Disease
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Therapy Type:

Enzyme Replacement Therapy
Substrate Reduction Therapy
Small Molecule Drugs
Others

By Application:

Glycogen Metabolism Disease
Lipid Metabolism Disease
Amino Acid Metabolism Disease
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

Brazil
Mexico
Rest of Latin America

Middle East

By Therapy Type:

Enzyme Replacement Therapy
Substrate Reduction Therapy
Small Molecule Drugs
Others

By Application:

Glycogen Metabolism Disease
Lipid Metabolism Disease
Amino Acid Metabolism Disease
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

GCC
Israel
Rest of Middle East

Africa

By Therapy Type:

Enzyme Replacement Therapy
Substrate Reduction Therapy
Small Molecule Drugs
Others

By Application:

Glycogen Metabolism Disease
Lipid Metabolism Disease
Amino Acid Metabolism Disease
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Country:

Central Africa
South Africa
North Africa

Company Profiles

Merck & Co., Inc.*

Company Overview
Application Portfolio
Financial Performance
Key Strategies
Recent Developments

Novartis AG
Amicus Therapeutics
AstraZeneca Plc
Boehringer Ingelheim
Shire Plc
Sanofi Genzyme
BioMarin Pharmaceutical, Inc.
Horizon Pharma Plc
GlaxoSmithKline Plc

“*” marked represents similar segmentation in other categories in the respective section.